Background: Against-label prescribing of statins with interacting drugs, such as cyclosporine, represents an important patient safety concern. Objective: To implement and evaluate the effectiveness of a clinical pharmacist patient-safety initiative to minimize against-label prescribing of statins with cyclosporine. Methods: Kaiser Permanente Colorado clinical pharmacists identified patients receiving both cyclosporine and against-label statin through prescription claims data. Academic detailing on this interaction was provided to health care providers. Clinical pharmacists collaborated with physicians to facilitate conversion to on-label statin. Conversion rates along with changes in low-density lipoprotein cholesterol (LDL-C) were assessed. Results: Of the 157 patients identified as taking cyclosporine, 48 were receiving concurrent statin therapy. Of these 48 patients, 33 (69%) were on an against-label statin regimen; 25 (76%) of these patients were converted to on-label statin. Overall, patients converted to on-label statin had a mean LDL-C prior to conversion of 82.9 (±26.4) mg/dL and mean LDL-C after conversion of 90.7 (±31.2) mg/dL (P = 0.21). In all, 17 patients (68%) were switched to pravastatin 20 mg daily and 8 patients (32%) to rosuvastatin 5 mg daily. In patients converted to pravastatin 20 mg daily, the mean LDL-C was 13.5 mg/dL higher than prior to conversion (P = 0.066). In patients converted to rosuvastatin 5 mg daily, the mean LDL-C was 3.8 mg/dL lower than prior to conversion (P = 0.73). Conclusion: Utilizing a patient-safety-centered approach, clinical pharmacists were able to reduce the number of patients on against-label statin with cyclosporine while maintaining a comparable level of LDL-C control.
LentineKLCostaSPWeirMR. Cardiac disease and evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2012;60:434-480. doi:10.1016/j.jacc.2012.05.008.
2.
CostanzoMRDipchandAStarlingR. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914-956. doi:10.1016/j.healun.2010.05.034.
3.
WannerCTonelliM; Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303-1309. doi:10.1038/ki.2014.31.
4.
HoldaasHFellströmBJardineAG. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet. 2003;361:2024-2031. doi:10.1016/S0140-6736(03)13638-0.
5.
MehraMRUberPAVivekananthanK. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol. 2002;40:1609-1614.
6.
KobashigawaJAKatznelsonSLaksH. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627. doi:10.1056/NEJM199509073331003.
7.
WenkeKMeiserBThieryJ. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107:93-97.
8.
KobashigawaJAMoriguchiJDLaksH. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005;24:1736-1740. doi:10.1016/j.healun.2005.02.009.
9.
US Food and Drug Administration. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed July 28, 2015.
10.
JacobsonTA.Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140-1146. doi:10.1016/j.amjcard.2004.07.080.
11.
StolcpartRSOlsonKLDelateTRasmussenJRehringTFMerenichJA.The risk for significant creatine kinase elevation with statins. Am J Cardiovasc Drugs. 2010;10:187-192. doi:10.2165/11536130-000000000-00000.
12.
ShanahanRLKerzeeJASandhoffBGCarrollNMMerenichJA.Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy. 2005;25:345-351. doi:10.1592/phco.25.3.345.61606.
13.
BottorffMB.Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97(8A):27C-31C. doi:10.1016/j.amjcard.2005.12.007.
14.
The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008;359:789-799. doi:10.1056/NEJMoa0801936.
Livalo (pitavastatin) [product information].Indianapolis, IN: Kowa Pharmaceuticals America Inc; 2012.
22.
IchimaruNTakaharaSKokadoY. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis. 2001;158:417-423.
23.
MaltzHCBalogDLCheighJS.Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother. 1999;33:1176-1179.
24.
KususMStapletonDDLertoraJJSimonEEDreisbachAW.Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci. 2000;320:394-397.
25.
OmarMAWilsonJP.FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-295.
26.
StoneNJRobinsonJGLichtensteinAH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25, pt B):2889-2934. doi:10.1016/j.jacc.2013.11.002.
27.
TuchschererRMNairKVGhushchyanVSaseenJJ.Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. Am J Cardiovasc Drugs. 2015;15:27-34. doi:10.1007/s40256-014-0096-x.
28.
AlfordJCSaseenJJAllenRRNairKV.Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Pharmacotherapy. 2012;32:623-630. doi:10.1002/j.1875-9114.2011.01090.x.
